Last €65.08 EUR
Change Today -0.227 / -0.35%
Volume 49.0
4XS On Other Exchanges
Symbol
Exchange
4XS is not on other exchanges.
As of 10:41 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (4XS) Snapshot

Open
€65.24
Previous Close
€65.31
Day High
€65.70
Day Low
€64.03
52 Week High
11/26/14 - €65.70
52 Week Low
04/30/14 - €47.50
Market Cap
47.8B
Average Volume 10 Days
147.9
EPS TTM
--
Shares Outstanding
733.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXPRESS SCRIPTS HOLDING CO (4XS)

express scripts holding co (4XS) Details

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. It operates in two segments, PBM and Other Business Operations. The company’s PBM services comprise retail network pharmacy administration; home delivery pharmacy; benefit design consultation; drug utilization review; drug formulary management; clinical solutions to improve health outcomes; an array of Medicare Part D, Medicaid, and health insurance marketplace; specialty pharmacy services, such as the distribution of fertility pharmaceuticals that require special handling or packaging; bio- pharmaceutical services, including reimbursement and logistics solutions; group purchasing organization administration; and consumer health and drug information services. It is also involved in the distribution of pharmaceuticals and medical supplies to providers and clinics; development of scientific evidence to guide the use of medicines; and provision of case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. Express Scripts Holding Company provides its PBM services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, and government health programs; and specialty services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

29,975 Employees
Last Reported Date: 02/20/14
Founded in 1986

express scripts holding co (4XS) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
Executive Vice President and General Counsel
Total Annual Compensation: $617.8K
Compensation as of Fiscal Year 2013.

express scripts holding co (4XS) Key Developments

Three Pharmacies Suing Express Scripts over Rejected Claims Compounded Drugs for Denying Coverage of Compounded Drugs

Three out-of-state pharmacies are suing Express Scripts Holding Company for denying coverage of compounded drugs. The suit, filed in the U.S. District Court in St. Louis, alleges that Express Scripts is trying to cut costs by denying payments to pharmacies for compounded drugs, which are mixed and prepared at certain pharmacies per a doctor's order. The lawsuit alleges the compound drugs were previously covered, and that denials started occurring this past June. The plaintiffs are Texas-based Annie's Apothecary; Cypress Compounding Pharmacy, also in Texas; and Louisiana-based Mason's Pharmacy.

Express Scripts Mulls Acquisitions

Express Scripts Holding Company (NasdaqGS:ESRX) is seeking acquisitions. Cathy Smith, Chief Financial Officer and Executive Vice President of Express Scripts, said, "The second priority will always be around strategic acquisitions. And the chart I'm going to show you next shows you that we have a great demonstrated track record around strategic acquisitions. Again we're going to be prudent and thoughtful and disciplined, like we always have been, but we'll also remain opportunistic around acquisitions."

Express Scripts Holding Company Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended Sep. 30, 2014; Revises Earnings Guidance for the Fourth Quarter and Year Ending Dec. 31, 2014

Express Scripts Holding Company reported unaudited consolidated financial results for the third quarter and nine months ended Sep. 30, 2014. For the quarter, revenues were $25,778.5 million against $25,915.6 million for the same period of last year. Operating income was $984.4 million against $875.5 million for the same period of last year. Income before income taxes was $798.3 million against $780.1 million for the same period of last year. Net income from continuing operations was $589.1 million or $0.78 per diluted share against $453.6 million or $0.54 per diluted share for the same period of last year. Net income attributable to the company was $582.3 million or $0.78 per diluted share against $426.7 million or $0.52 per diluted share for the same period of last year. EBITDA from continuing operations, attributable to the company was $1,524.6 million against $1,478.4 million for the same period of last year. Adjusted EBITDA from continuing operations, attributable to the company was $1,739.2 million against $1,656.9 million for the same period of last year. For the nine months, revenues were $74,574.5 million against $78,317.4 million for the same period of last year. Operating income was $2,659.6 million against $2,722.9 million for the same period of last year. Income before income taxes was $2,235.7 million against $2,304.0 million for the same period of last year. Net income from continuing operations was $1,446.3 million or $1.86 per diluted share against $1,408.0 million or $1.67 per diluted share for the same period of last year. Net income attributable to the company was $1,425.8 million or $1.86 per diluted share against $1,342.7 million or $1.62 per diluted share for the same period of last year. EBITDA from continuing operations, attributable to the company was $4,297.3 million against $4,522.9 million for the same period of last year. Adjusted EBITDA from continuing operations, attributable to the company was $4,945.4 million against $4,995.9 million for the same period of last year. Net cash flows provided by operating activities was $1,624.6 million against $1,822.4 million for the same period of last year. Purchases of property and equipment was $327.0 million against $274.6 million for the same period of last year. For the fourth quarter of 2014, based on year-to-date adjusted earnings per share of $3.51, this equates to a fourth quarter earnings per share range of $1.36 to $1.40. For the year ending Dec. 31, 2014, the company now expects adjusted earnings per diluted share attributable to the company to be in the range of $4.86 to $4.90 against previous guidance of $4.84 to $4.92; effective income tax rate to be in the range of 37.6% to 37.8% against previous guidance of 38.0% to 38.2%; adjusted EBITDA to be in the range of $6,750 to $6,850 million against previous guidance of $6,775 to $6,925 million; cash flow from operations to be in the range of $4,550 to $5,150 million against previous guidance of $4,550 to $5,150 million; and capital expenditures to be in the range of $400 to $450 million against previous guidance of $400 to $450 million. Earnings guidance to a range of $4.86 to $4.90 per diluted share. This range maintains the previously guided midpoint of $4.88 and represents growth of 18% to 19% year-over-year excluding United.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4XS:GR €65.08 EUR -0.227

4XS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $81.05 USD +0.07
McKesson Corp $207.90 USD -1.04
Kroger Co/The $58.78 USD -0.045
Walgreen Co $68.20 USD +0.39
WellPoint Inc $127.07 USD -0.08
View Industry Companies
 

Industry Analysis

4XS

Industry Average

Valuation 4XS Industry Range
Price/Earnings 32.4x
Price/Sales 0.6x
Price/Book 3.0x
Price/Cash Flow 15.5x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit www.express-scripts.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.